Of note, Pasqua et al. [105] conducted a randomized, double-blind crossover trial at the Research Institute of the McGill University Health Centre in Montreal (Quebec, Canada) to evaluate whether once-weekly subcutaneous semaglutide, compared to placebo, improves glucose control and other non-glycemic outcomes in adults with T1D while using an automated insulin delivery (AID) system. This evidence concerns the gene INS and type 1 diabetes mellitus.